Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

since several batches of product that were manufactured during the latter part of the second quarter were not shipped until the third quarter, when these revenues will be recorded.

Total costs and expenses decreased $1,954,000 to $6,491,000 in the second quarter of FY 2009 from $8,445,000 in the same prior year quarter, a decrease of 23%. The decrease was primarily related to planned reductions in R&D costs associated with Peregrine's preclinical programs. These reductions were implemented to maximize the R&D resources available to advance the company's priority clinical product candidates bavituximab and Cotara(R). R&D expenses were $4,301,000 in the second quarter of FY 2009, compared to $5,100,000 in the second quarter of FY 2008. The decrease in R&D expense was achieved despite an increase in clinical activity during the quarter. SG&A expenses were down $416,000 to $1,527,000 for the second quarter of FY 2009 compared to $1,943,000 for the comparable period in FY 2008, a decrease of 21%. This decrease reflects a reduction in SG&A expenses across the board, reflecting the company's focus on stringent management of all discretionary expense categories.

At October 31, 2008, the company had $8,210,000 in cash and cash equivalents. After the close of the quarter, on December 9, 2008, Peregrine entered into an agreement for a non-convertible term loan with an initial tranche of $5 million that will be funded upon closing, with an option to acquire a second $5 million tranche in the future, upon Peregrine's satisfaction of certain additional conditions.

"This past quarter was highlighted by significant milestones for both our bavituximab cancer and anti-viral programs," said Steven W. King, president and CEO of Peregrine. "For the first time, we reported patient enrollment underway in three bavituximab Phase II cancer trials, along with encouraging updated results from o
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Getting breast implants is a choice, but deciding ... to medical necessity. Either way, women should know what to ... says Robert Kraft, MD, Plastic Surgeon with Advanced Dermatology, ... performed each year in the United States, according to the ... procedures stem from three main problems: the breast implant has ...
(Date:7/22/2014)... A new and technologically unique procedure called ... that are surprising even the most skeptical plastic surgeons. ... radio frequency, ThermiTight has been dubbed “InjectableRF” because it ... to “inject” heat to the tissues which cause sagging ... solution for skin laxity produces results in weeks, with ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 On Monday, September ... Charity Golf Outing honoring Mike McGuriman-Motorola Solutions at The Knoll ... outing begins with registration and lunch at 11 a.m. ... and prizes. Price increases to $250 after September 7th. ... for $100 per person. The dinner will include a ...
(Date:7/21/2014)... MINNEAPOLIS, Minnesota (PRWEB) July 21, 2014 ... on providing service, support, education, and add-ons for ... Microsoft Dynamics Inner Circle, an elite group of ... the globe with sales achievements that rank them ... global network of partners. Members of the Microsoft ...
(Date:7/21/2014)... It,s human nature to hate losing. , Unfortunately, ... potentially abandoning a solid strategy and thus increasing your ... one conclusion of a Brigham Young University study published ... The finding is based on an analysis of two ... researchers focused on whether coaches adjusted their personnel following ...
Breaking Medicine News(10 mins):Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 2Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 3Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2
... , CHICAGO, Sept. 1 In ... which shows young athletes with repeated brain injuries are at ... Association (IATA) and the Chicago Institute of Neurosurgery and Neuroresearch ... and monitoring concussions. The complimentary card is an educational tool ...
... , , , FRANKLIN LAKES, N.J., Sept. 1 ... announced today that it would present at the following investor healthcare conferences in September: , ... September 9, 2009, ... Conference, September 14, 2009, ...
... than laparoscopic surgery, study finds , TUESDAY, Sept. 1 ... pelvic pain by disrupting nerve connections failed to improve ... researchers say. , The nerve-disruption procedure "did not alleviate ... irrespective of the presence or absence of mild endometriosis," ...
... , , WARSAW, Ind., Sept. 1 Zimmer ... be participating in the following investor conferences during the month of September: , ... Conference 2009 in Boston, Mass., on September 9, 2009, at 11:30 a.m. Eastern ... New York, N.Y., on September 14, 2009, at 8:35 a.m. Eastern Time; and ...
... "Saturday ... Dr. Lonnie Paulos now beginning its second year , ... Gulf Breeze, FL (Vocus) September 1, 2009 -- ... orthopaedic exams and assessments to high school and collegiate athletes on Saturday mornings. ...
... , KANSAS CITY, Mo., Sept. 1 ... with medical challenges often unique to members of the military. From ... some of the most pressing conditions confronting the health care system ... Release, go to: http://www.prnewswire.com/mnr/militaryhealth/39824/ , ...
Cached Medicine News:Health News:Illinois Athletic Trainers and Physicians Offer Handy Wallet Card to Tackle Concussions 'Head On' 2Health News:Two Treatments Equally Effective for Chronic Pelvic Pain 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 3Health News:Video: Physical and Mental Health of U.S. Warfighter Is Focus of Military Health Research Forum 2
(Date:7/21/2014)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... (FDA) accepted the company,s Investigational New Drug (IND) application ... efficacy of AVP-786, Avanir,s next generation compound. The company ... adjunctive treatment of major depressive disorder (MDD) during the ... endorsement of this Phase II study by the division ...
(Date:7/21/2014)... 21, 2014 Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and its associated pain, ... the preclinical development of a small molecule inhibitor targeting ... The Myc protein has also been recognized as an ... is involved as a dominant factor in most human ...
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Inc. (OTCPK: SNDY) is pleased to announce that the Company ... in the amount of $90,005. The revenue for the three ... fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers ... growth in 2011 through new product development, new product sales ...
... Ireland, Jan. 27, 2011 Tibotec Pharmaceuticals today ... to generic manufacturers including Hetero Drugs Limited, Matrix ... Aspen Pharmacare of South Africa to manufacture, market ... rilpivirine hydrochloride (TMC278), pending ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 3Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 4